[Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria].

Zhonghua fu chan ke za zhi · 2001 · vol. 36(4) , pp. 218–21 · PMID:11783365 · W2378397449
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-08

This study cultured human eutopic and ectopic endometria with mifepristone and found it dose-dependently suppressed ER and PR expression in both.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate the effects of mifepristone on expression of estrogen receptor (ER) and progesterone receptor (PR) in cultured human eutopic and ectopic endometria. METHODS: Endometrial (n = 22) and endometriotic (n = 12) tissues, obtained from patients with endometriosis, were cultured with and without mifepristone (1 x 10(-6) mol/L, 1 x 10(-4) mol/L) for 7-10 days. The expressions of ER, PR were determined by semi-quantitative immunocytochemistry method. Thirteen normal endometrial samples served as controls. RESULTS: The expressions of ER and PR in normal and eutopic endometrial cells showed the same cyclic pattern. The only difference was the significantly higher PR glandular content in eutopic endometria of endometriosis patients, as compared with normal controls [histochemistry score (H-score) 2.77 +/- 0.32 Vs 2.20 +/- 0.26 P < 0.05]. On the contrary, the ER, PR expressions in ectopic endometrial cells were significantly lower only during the proliferative phase (ER: gland 0.65-2.17 Vs 1.50-3.23, stroma 0.45-1.03 Vs 0.80-1.96; PR: gland 0.55-1.77 Vs 1.55-3.34, stroma 0.40-1.27 Vs 0.98-2.50; P < 0.05-0.01); significantly higher only during the late secretory phase (ER: gland 3.27 +/- 0.31 Vs 0.28 +/- 0.11, stroma 1.87 +/- 0.31 Vs 0.26 +/- 0.15; PR: gland 3.33 +/- 0.23 Vs 0.36 +/- 0.23) as compared with those of eutopic endometria. 10(-6)-10(-4) mol/L of mifepristone significantly suppressed the expressions of ER, PR in both eutopic and ectopic endometrial cells of endometriosis patients (P < 0.01) in a dose-dependent manner. CONCLUSIONS: Expression of ER, PR of endometriotic cells differed significantly from that of endometrial cells of patients with or without endometriosis. The down-regulatory effect on ER and PR may be one of the therapeutic mechanism of mifepristone on endometriosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Choristoma Endometrium Hormone Antagonists Mifepristone Receptors, Estrogen Receptors, Progesterone Adult Cells, Cultured Choristoma Choristoma Endometriosis Endometriosis Endometriosis Endometrium Female Hormone Antagonists Humans Middle Aged Mifepristone Receptors, Estrogen

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:13.417725+00:00
License: CC0 · commercial use OK